TABLE 5.

Subjects who experienced a breakthrough invasive fungal infection after removal from study drug that was caused by the same Candida species identified as a colonizer

Prophylactic agent	IFI and colonizing species	Day of IFI onset/duration of prophylaxis (days)/time since last dose (days)	Results for isolates cultured from subjects with an invasive fungal infection
			Culture day/sourcea	MIC (μg/ml)
				Posaconazole	Fluconazole	Itraconazole
Posaconazole	C. glabrata	75/33/42	59/mouth	1	16	1
			75/blood	NAb	NA	NA
	C. glabrata	165/138/27	35/mouth	4	64	8
			60/mouth	4	>64	4
			88/mouth	2	>64	2
	C. glabrata	25/3/22	1/stool	4	16	8
			3/stool	0.5	8	1
			23/stool	0.125	4	0.125
			25/blood	0.5	8	2
	C. glabrata	37/9/28	7/stool	1	8	1
			9/urine	NA	NA	NA
			10/stool	1	8	2
			14/stool	NA	NA	NA
			37/blood	NA	NA	NA
	C. tropicalis	45/24/21	−3/stool	<0.015	0.25	0.03
			−3/pharynx	<0.015	0.5	0.03
			2/stool	<0.015	0.25	<0.015
			2/pharynx	<0.015	0.25	0.03
			9/stool	<0.015	0.5	0.03
			45/blood	NA	NA	NA
Fluconazole	C. glabrata	31/28/3	16/mouth	<0.5	<2	<1
			31/mouth	<0.5	<4	<1
	C. glabrata	143/116/27c	1/mouth	0.5	16	1
			12/mouth	2	64	4
			62/mouth	4	64	8
			85/mouth	4	64	8
			111/mouth	4	64	>8
			143/blood	NA	NA	NA
	C. glabrata	168/113/55	−2/mouth	1	64	1
			15/mouth	2	64	4
			43/mouth	2	64	2
			176/mouth	4	>64	2
	C. glabrata	172/114/58d	−2/mouth	0.5	16	1
			56/mouth	0.25	4	0.5
			86/mouth	1	16	2
			114/mouth	2	32	8
			172/blood	NA	NA	NA
			177/mouth	1	32	1
	C. krusei	19/6/13	1/pharynx	0.06	32	0.125
			6/stool	0.125	64	0.5
			6/pharynx	0.06	32	0.5
			16/stool	0.25	64	0.25
			16/pharynx	0.25	64	0.5
			19/blood	0.06	32	0.25

^aCultures of samples from the from mouth (study 1, HSCT recipients) and from the stool and pharynx (study 2, subjects with AML or MDS) were part of a surveillance program; blood and urine cultures were performed in cases with an IFI.

^bNA, not available.

^cSubject 002.

^dSubject 497.